A Faegre Drinker team advised medical device company Boston Scientific in its acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System. The transaction includes an upfront payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years and is anticipated to close in the first half of 2024, subject to customary closing conditions.
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, the company advances science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.
Read Boston Scientific’s press release for more information on the deal.
